Biogen, Inc. (NASDAQ/BGEN) today announced that Peter N. Kellogg has been appointed Vice President, Finance and Chief Financial Officer. Mr. Kellogg reports to James C. Mullen, President and Chief Executive Officer.

Mr. Kellogg joins Biogen from PepsiCo Inc., where he was most recently Senior Vice President, PepsiCo E-Commerce. From 1987-2000, he served in a variety of senior financial, international and general management positions at PepsiCo, including Vice President and General Manager-Pepsi, South Franchise Business Unit; Vice President and Chief Financial Officer, Central/Eastern Europe and Russia, Pepsi-Cola International; Vice President and Chief Financial Officer, Frito-Lay Latin America, and Senior Vice President and Chief Financial Officer, Frito-Lay International. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Arthur Andersen & Co. and Booz Allen & Hamilton. He received a B.S.E. in Civil Engineering from Princeton University and an M.B.A. from The Wharton School.

Mr. Mullen said, “We are delighted that a financial executive with Peter Kellogg´s range of experience is joining Biogen. His experience includes leading and building financial operations at divisional, regional and corporate levels, as well as international assignments. Peter also has significant strategic planning and general management experience. This gives him a great range of experience that positions him to meet the many challenges of growing a company like Biogen and he will be a significant addition to our senior management team.”

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company´s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products ( Prescribing Information ). Biogen´s research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen´s Homepage on the World Wide Web at